Mitsubishi Tanabe Pharma Corporation’s billion-dollar bid nearly six years ago for NeuroDerm Ltd. and its drug for Parkinson’s disease looks likely to pay off as the Israeli drug developer announced positive Phase III results from the drug, in a field that has seen considerable development and multiple billion-dollar collaboration deals in recent years.
NeuroDerm said 9 January that the Phase III BouNDless trial of ND0162 met its primary endpoint of “on” time without troublesome dyskinesia – also known as “good on” time – along with positive and clinically meaningful results for the key secondary endpoint of “off” time
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?